title: Mineral Levels in Thalassaemia Major Patients Using Different Iron Chelators.
abstract: The goal of the present study was to determine the levels of minerals in chronically transfused thalassaemic patients living in Antalya, Turkey and to determine mineral levels in groups using different iron chelators. Three iron chelators deferoxamine, deferiprone and deferasirox have been used to remove iron from patients' tissues. There were contradictory results in the literature about minerals including selenium, zinc, copper, and magnesium in thalassaemia major patients. Blood samples from the 60 thalassaemia major patients (the deferoxamine group, n = 19; the deferiprone group, n = 20 and the deferasirox group, n = 21) and the controls (n = 20) were collected. Levels of selenium, zinc, copper, magnesium, and iron were measured, and all of them except iron showed no significant difference between the controls and the patients regardless of chelator type. Serum copper levels in the deferasirox group were lower than those in the control and deferoxamine groups, and serum magnesium levels in the deferasirox group were higher than those in the control, deferoxamine and deferiprone groups. Iron levels in the patient groups were higher than those in the control group, and iron levels showed a significant correlation with selenium and magnesium levels. Different values of minerals in thalassaemia major patients may be the result of different dietary intake, chelator type, or regional differences in where patients live. That is why minerals may be measured in thalassaemia major patients at intervals, and deficient minerals should be replaced. Being careful about levels of copper and magnesium in thalassaemia major patients using deferasirox seems to be beneficial.
authors.affiliation: Faculty of Medicine, Akdeniz University, Antalya, Turkey.
authors.forename: Gizem Esra
authors.initials: GE
authors.lastname: Genc
authors.affiliation: Faculty of Medicine, Akdeniz University, Antalya, Turkey.
authors.forename: Zeynep
authors.initials: Z
authors.lastname: Ozturk
authors.affiliation: Faculty of Medicine, Akdeniz University, Antalya, Turkey. sgumuslu@akdeniz.edu.tr.
authors.forename: Saadet
authors.initials: S
authors.lastname: Gumuslu
authors.affiliation: Faculty of Medicine, Akdeniz University, Antalya, Turkey.
authors.forename: Alphan
authors.initials: A
authors.lastname: Kupesiz
mesh_terms: D001565:Benzoates / Q000627:therapeutic use*; D000077588:Deferasirox; D000077543:Deferiprone; D005260:Female; D006801:Humans; D007501:Iron / Q000097:blood*; D007502:Iron Chelating Agents / Q000627:therapeutic use*; D008297:Male; D008903:Minerals / Q000097:blood*; D011728:Pyridones / Q000627:therapeutic use*; D014230:Triazoles / Q000627:therapeutic use*; D055815:Young Adult; D017086:beta-Thalassemia / Q000097:blood*
chemical_list: D001565:Benzoates; D007502:Iron Chelating Agents; D008903:Minerals; D011728:Pyridones; D014230:Triazoles; D000077543:Deferiprone; D007501:Iron; D000077588:Deferasirox
keywords: Copper; Iron; Iron chelator; Magnesium; Selenium; Thalassaemia; Zinc